Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of MK-5160 in T1DM and T2DM
NCT03095651Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-5160 in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (8 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing an Adverse Event up to 33 days, Number of Participants Discontinuing Study Drug Due to an AE up to 12 days and 1 more. Started Apr 2017; status: completed.
02
Drugs
MK-5160
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03095651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095651.